Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®
Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®
Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®
Submitted by
admin
on July 7, 2022 - 10:41am
Source:
BioSpace
News Tags:
Alvotech
AVT06
biosimilars
clinical trials
Eylea
Headline:
Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®
snippet:
AVT06 is the third biosimilar candidate developed by Alvotech to enter clinical studies
Eylea® (aflibercept) is used for the treatment of eye disorders and reached global sales of nearly US$10 billion in 2021
Do Not Allow Advertisers to Use My Personal information
